Search

Sean Mcgarry

Examiner (ID: 6820, Phone: (571)272-0761 , Office: P/1674 )

Most Active Art Unit
1635
Art Unit(s)
1635, 1674, 1621, 1809, 1624, 1805
Total Applications
1927
Issued Applications
1068
Pending Applications
344
Abandoned Applications
554

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17595773 [patent_doc_number] => 20220145347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => HIGH-EFFICIENCY RECONSTITUTION OF RNA MOLECULES [patent_app_type] => utility [patent_app_number] => 17/486488 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486488 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/486488
High-efficiency reconstitution of RNA molecules Sep 26, 2021 Issued
Array ( [id] => 17807765 [patent_doc_number] => 20220259600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/484386 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484386 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/484386
COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION Sep 23, 2021 Abandoned
Array ( [id] => 17334572 [patent_doc_number] => 20220000903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => PHARMACEUTICAL COMPOSITION THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN, PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B, AND SCREENING METHOD [patent_app_type] => utility [patent_app_number] => 17/483183 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483183 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/483183
PHARMACEUTICAL COMPOSITION THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN, PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B, AND SCREENING METHOD Sep 22, 2021 Abandoned
Array ( [id] => 17776851 [patent_doc_number] => 20220243200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/481679 [patent_app_country] => US [patent_app_date] => 2021-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17481679 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/481679
COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION Sep 21, 2021 Pending
Array ( [id] => 17312823 [patent_doc_number] => 20210401871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => OLIGONUCLEOTIDES TO TREAT EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/475795 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17475795 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/475795
OLIGONUCLEOTIDES TO TREAT EYE DISEASE Sep 14, 2021 Abandoned
Array ( [id] => 17314859 [patent_doc_number] => 20210403907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => ARC-BASED CAPSIDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/473209 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17473209 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/473209
ARC-BASED CAPSIDS AND USES THEREOF Sep 12, 2021 Abandoned
Array ( [id] => 17609802 [patent_doc_number] => 20220152081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS [patent_app_type] => utility [patent_app_number] => 17/469530 [patent_app_country] => US [patent_app_date] => 2021-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17469530 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/469530
Agents and methods for treating pancreatic ductal adenocarcinomas Sep 7, 2021 Issued
Array ( [id] => 20077548 [patent_doc_number] => 12351598 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use [patent_app_type] => utility [patent_app_number] => 17/461797 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 105 [patent_figures_cnt] => 181 [patent_no_of_words] => 83131 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461797 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/461797
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use Aug 29, 2021 Issued
Array ( [id] => 17314872 [patent_doc_number] => 20210403920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER [patent_app_type] => utility [patent_app_number] => 17/411265 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411265 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/411265
Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer Aug 24, 2021 Issued
Array ( [id] => 17292524 [patent_doc_number] => 20210388363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA [patent_app_type] => utility [patent_app_number] => 17/411932 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411932 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/411932
Modulators and modulation of the receptor for advanced glycation end-products RNA Aug 24, 2021 Issued
Array ( [id] => 17414351 [patent_doc_number] => 20220049255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => MODULATING THE CELLULAR STRESS RESPONSE [patent_app_type] => utility [patent_app_number] => 17/411313 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411313 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/411313
Modulating the cellular stress response Aug 24, 2021 Issued
Array ( [id] => 19975901 [patent_doc_number] => 12343357 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Compositions and methods for modulating MECP2 expression [patent_app_type] => utility [patent_app_number] => 17/408920 [patent_app_country] => US [patent_app_date] => 2021-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17727 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17408920 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/408920
Compositions and methods for modulating MECP2 expression Aug 22, 2021 Issued
Array ( [id] => 17720755 [patent_doc_number] => 20220213475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => DUAL TARGETING siRNA AGENTS [patent_app_type] => utility [patent_app_number] => 17/402459 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402459 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/402459
DUAL TARGETING siRNA AGENTS Aug 12, 2021 Abandoned
Array ( [id] => 17256842 [patent_doc_number] => 20210369827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => COMBINATION OF VACCINATION AND OX40 AGONISTS [patent_app_type] => utility [patent_app_number] => 17/396760 [patent_app_country] => US [patent_app_date] => 2021-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17396760 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/396760
Combination of vaccination and OX40 agonists Aug 7, 2021 Issued
Array ( [id] => 17200076 [patent_doc_number] => 20210340171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => ANTISENSE NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 17/375877 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17375877 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/375877
ANTISENSE NUCLEIC ACIDS Jul 13, 2021 Abandoned
Array ( [id] => 17312903 [patent_doc_number] => 20210401951 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => MRNA THERAPY FOR POMPE DISEASE [patent_app_type] => utility [patent_app_number] => 17/369783 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369783 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/369783
MRNA therapy for pompe disease Jul 6, 2021 Issued
Array ( [id] => 17299909 [patent_doc_number] => 20210395748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PROINFLAMMATORY CYTOKINE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/366835 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366835 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/366835
Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors Jul 1, 2021 Issued
Array ( [id] => 17505480 [patent_doc_number] => 20220098582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => Methods for Treatment of Alport Syndrome [patent_app_type] => utility [patent_app_number] => 17/366796 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366796 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/366796
Methods for Treatment of Alport Syndrome Jul 1, 2021 Abandoned
Array ( [id] => 18825415 [patent_doc_number] => 11840686 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-12 [patent_title] => Modulation of prekallikrein (PKK) expression [patent_app_type] => utility [patent_app_number] => 17/367096 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 66203 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367096 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/367096
Modulation of prekallikrein (PKK) expression Jul 1, 2021 Issued
Array ( [id] => 18552429 [patent_doc_number] => 20230250438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => Blood-Brain Barrier Penetrating Aptamer and Use Thereof [patent_app_type] => utility [patent_app_number] => 18/013055 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013055 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/013055
Blood-Brain Barrier Penetrating Aptamer and Use Thereof Jun 28, 2021 Pending
Menu